loader
Please Wait
Applying Filters...
Close
4

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Entresto, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Entresto

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass

    PharmaCompass Sponsored Ads

    PharmaCompass Sponsored Ads

    2D Structure
    Also known as: Sacubitril valsartan sodium hydrate, Sacubitril mixture with valsartan, Wb8ft61183, Lcz 696, Sacubitril valsartan sodium hydrate (jan), Sacubitril valsartan sodium hydrate [jan]
    Molecular Formula
    C96H120N12Na6O21
    Molecular Weight
    1916.0  g/mol
    InChI Key
    ZASXKEGREHRXDL-CAWNUZPDSA-H
    FDA UNII
    WB8FT61183
    Sacubitril/Valsartan is a combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate
    2.1.2 InChI
    InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
    2.1.3 InChI Key
    ZASXKEGREHRXDL-CAWNUZPDSA-H
    2.1.4 Canonical SMILES
    CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
    2.1.5 Isomeric SMILES
    CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
    2.2 Other Identifiers
    2.2.1 UNII
    WB8FT61183
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate

    2. Lcz 696

    3. Lcz-696

    4. Lcz696

    5. Sacubitril And Valsartan Drug Combination

    6. Sacubitril And Valsartan Sodium Anhydrous Drug Combination

    7. Sacubitril And Valsartan Sodium Hydrate Drug Combination

    8. Sacubitril Valsartan Drug Combination

    9. Sacubitril Valsartan Sodium Anhydrous

    10. Sacubitril Valsartan Sodium Hydrate

    11. Sacubitril-valsartan

    12. Sacubitril-valsartan Sodium Anhydrous Drug Combination

    13. Sacubitril-valsartan Sodium Hydrate Drug Combination

    14. Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) Hemipentahydrate

    2.3.2 Depositor-Supplied Synonyms

    1. Sacubitril Valsartan Sodium Hydrate

    2. Sacubitril Mixture With Valsartan

    3. Wb8ft61183

    4. Lcz 696

    5. Sacubitril Valsartan Sodium Hydrate (jan)

    6. Sacubitril Valsartan Sodium Hydrate [jan]

    7. Entresto (tn)

    8. Unii-wb8ft61183

    9. Valsartan Mixture With Ahu-377

    10. Ex-a2849

    11. Mfcd29477717

    12. 3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate

    13. Ac-29037

    14. Sucabitril Valsartan Sodium Hydrate

    15. Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) Hemipentahydrate

    16. D10226

    17. Valsartan Ahu-377 Sodium Hemipentahydrate

    18. Q27292546

    19. L-valine, N-(1-oxopentyl)-n-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Compd. With .alpha.-ethyl (.alpha.r,.gamma.s)-.gamma.-((3-carboxy-1-oxopropyl)amino)-.alpha.-methyl(1,1'-biphenyl)-4-pentanoate, Sodium Salt, Hydrate (2:2:6:5)

    20. L-valine, N-(1-oxopentyl)-n-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Compd. With Alpha-ethyl(alphar,gammas)-gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl(1,1'-biphenyl)-4-pentanoate, Sodium Salt, Hydrate (2:2:6:5)

    2.4 Create Date
    2013-05-27
    3 Chemical and Physical Properties
    Molecular Weight 1916.0 g/mol
    Molecular Formula C96H120N12Na6O21
    Hydrogen Bond Donor Count7
    Hydrogen Bond Acceptor Count29
    Rotatable Bond Count40
    Exact Mass1915.8110694 g/mol
    Monoisotopic Mass1914.8077146 g/mol
    Topological Polar Surface Area396 Ų
    Heavy Atom Count135
    Formal Charge0
    Complexity1140
    Isotope Atom Count0
    Defined Atom Stereocenter Count6
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count15
    4 Drug and Medication Information
    4.1 Drug Indication

    Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Angiotensin Receptor Antagonists

    Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. (See all compounds classified as Angiotensin Receptor Antagonists.)

    5.2 ATC Code

    C09DX04

    Post Enquiry
    POST ENQUIRY